| 1 |
Karami H, Shirvani Shiri M, Ebadi Fard Azar F, Bagheri Lankarani K, Ghahramani S, Rezapour A, Tatari M, Heidari Javargi Z. Factors associated with health-related quality of life in patients with Crohn's disease in Iran: A prospective observational study. Front Med (Lausanne) 2022;9:1091330. [PMID: 36760884 DOI: 10.3389/fmed.2022.1091330] [Reference Citation Analysis]
|
| 2 |
Brown SC, Whelan K, Frampton C, Wall CL, Gearry RB, Day AS. Food-Related Quality of Life in Children and Adolescents With Crohn's Disease. Inflamm Bowel Dis 2022;28:1838-43. [PMID: 35166341 DOI: 10.1093/ibd/izac010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 3 |
Di Candido F. Quality of Life in Inflammatory Bowel Diseases (IBDs) Patients after Surgery. Rev Recent Clin Trials 2022;17:227-39. [PMID: 35959618 DOI: 10.2174/1574887117666220811143426] [Reference Citation Analysis]
|
| 4 |
Alhadab AA, AlMahamed SN, Hassan IE, Hammo AH. The impact of inflammatory bowel diseases on the quality of life of Saudi pediatric patients: A cross-sectional study. Saudi J Gastroenterol 2022;28:448-55. [PMID: 35946259 DOI: 10.4103/sjg.sjg_162_22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Vicente Lidón R, García López S, Corsino Roche P, Boudet Barraca JM, Sanz Segura P, García Cámara P, Sierra Moros E, Gomollón García F. Translation into Spanish and validation of a short questionnaire to measure the control of inflammatory bowel disease from the patient's perspective: IBD-Control, EII-Control. Gastroenterología y Hepatología (English Edition) 2022;45:524-534. [DOI: 10.1016/j.gastre.2022.07.001] [Reference Citation Analysis]
|
| 6 |
Radford SJ, Moran GW, Czuber-dochan W. The impact of Inflammatory Bowel Disease related fatigue on Health-Related Quality of Life: a qualitative semi-structured interview study. Journal of Research in Nursing. [DOI: 10.1177/17449871211061048] [Reference Citation Analysis]
|
| 7 |
Jedel S, Beck T, Swanson G, Hood MM, Voigt RM, Gorenz A, Jakate S, Raeisi S, Hobfoll S, Keshavarzian A. Mindfulness Intervention Decreases Frequency and Severity of Flares in Inactive Ulcerative Colitis Patients: Results of a Phase II, Randomized, Placebo-Controlled Trial. Inflamm Bowel Dis 2022;28:1872-92. [PMID: 35661212 DOI: 10.1093/ibd/izac036] [Reference Citation Analysis]
|
| 8 |
De Gregorio M, Lee T, Krishnaprasad K, Amos G, An YK, Bastian-Jordan M, Begun J, Borok N, Brown DJM, Cheung W, Connor SJ, Gerstenmaier J, Gilbert LE, Gilmore R, Gu B, Kutaiba N, Lee A, Mahy G, Srinivasan A, Thin L, Thompson AJ, Welman CJ, Yong EXZ, De Cruz P, van Langenberg D, Sparrow MP, Ding NS. Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas. Clin Gastroenterol Hepatol 2022;20:1306-14. [PMID: 34389484 DOI: 10.1016/j.cgh.2021.07.053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 9 |
Nag A, Romero B. Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn's disease in adults with moderate-to-severe disease. Health Qual Life Outcomes 2022;20:75. [PMID: 35525935 DOI: 10.1186/s12955-022-01975-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 10 |
Mendonça CM, Correa Neto IJF, Rolim ADS, Robles L. INFLAMMATORY BOWEL DISEASES: CHARACTERISTICS, EVOLUTION, AND QUALITY OF LIFE. ABCD, arq bras cir dig 2022;35. [DOI: 10.1590/0102-672020210002e1653] [Reference Citation Analysis]
|
| 11 |
Zavala-solares MR, Salazar-salas L, Yamamoto-furusho JK. Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 2021;44:711-718. [DOI: 10.1016/j.gastre.2021.03.005] [Reference Citation Analysis]
|
| 12 |
Montenegro-Burke JR, Kok BP, Guijas C, Domingo-Almenara X, Moon C, Galmozzi A, Kitamura S, Eckmann L, Saez E, Siuzdak GE, Wolan DW. Metabolomics activity screening of T cell-induced colitis reveals anti-inflammatory metabolites. Sci Signal 2021;14:eabf6584. [PMID: 34582249 DOI: 10.1126/scisignal.abf6584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 13 |
Ye XQ, Cai J, Yu Q, Cao XC, Chen Y, Rao MX, Chen BL, He Y, Zeng ZR, Chen H, Lin YM, Cao Q, Chen MH, Zhang SH. Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study. Gastroenterol Rep (Oxf) 2021;9:329-38. [PMID: 34567565 DOI: 10.1093/gastro/goaa069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 14 |
Vicente Lidón R, García López S, Corsino Roche P, Boudet Barraca JM, Sanz Segura P, García Cámara P, Sierra Moros E, Gomollón García F. Translation into Spanish and validation of a short questionnaire to measure the control of inflammatory bowel disease from the patient's perspective: IBD-Control, EII-Control. Gastroenterol Hepatol 2021:S0210-5705(21)00243-0. [PMID: 34428475 DOI: 10.1016/j.gastrohep.2021.08.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 15 |
Rogers CC, Moutinho TJ Jr, Liu X, Valdez RS. Designing Consumer Health Information Technology to Support Biform and Articulation Work: A Qualitative Study of Diet and Nutrition Management as Patient Work. JMIR Hum Factors 2021;8:e27452. [PMID: 34383664 DOI: 10.2196/27452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 16 |
Newton L, Delbecque L, Coşkun U, Symonds T, Clegg J, Hunter T. A qualitative study to explore symptoms and impacts of pediatric and adolescent Crohn's disease from patient and caregiver perspective. J Patient Rep Outcomes 2021;5:49. [PMID: 34170423 DOI: 10.1186/s41687-021-00321-1] [Reference Citation Analysis]
|
| 17 |
Bonnaud G, Haennig A, Altwegg R, Caron B, Boivineau L, Zallot C, Gilleta de Saint-Joseph C, Moreau J, Gonzalez F, Reynaud D, Faure P, Aygalenq P, Combis JM, Peyrin-Biroulet L. Real-life pilot study on the impact of the telemedicine platform EasyMICI-MaMICI(®) on quality of life and quality of care in patients with inflammatory bowel disease. Scand J Gastroenterol 2021;56:530-6. [PMID: 33691075 DOI: 10.1080/00365521.2021.1894602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Zavala-Solares MR, Salazar-Salas L, Yamamoto-Furusho JK. Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease. Gastroenterol Hepatol 2021:S0210-5705(21)00116-3. [PMID: 33872624 DOI: 10.1016/j.gastrohep.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 19 |
Santos CHMD, Galindo ACA, Silva BAD, Dantas CR, Guilherme IADA, Gomes JEBN, Dallacqua KM, Souza MPD, Senna PS. Comparative analysis of anxiety and depression prevalence between individuals with and without inflammatory bowel disease. Journal of Coloproctology 2021;40:339-44. [DOI: 10.1016/j.jcol.2020.07.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 20 |
Engel K, Homsi M, Suzuki R, Helvie K, Adler J, Plonka C, Zimmermann E. Newly Diagnosed Patients with Inflammatory Bowel Disease: The Relationship Between Perceived Psychological Support, Health-Related Quality of Life, and Disease Activity. Health Equity 2021;5:42-8. [PMID: 33681688 DOI: 10.1089/heq.2020.0053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 21 |
Haapamäki J. Health-Related Quality of Life and Inflammatory Bowel Disease. Encyclopedia of Quality of Life and Well-Being Research 2021. [DOI: 10.1007/978-3-319-69909-7_3838-2] [Reference Citation Analysis]
|
| 22 |
Neuman MD, Kappelman MD, Israel E, Ellenberg SS, Girman C, Robb J, Rabinowitz A, Trontell A. Real-world experiences with generating real-world evidence: Case Studies from PCORI's pragmatic clinical Studies program. Contemp Clin Trials 2020;98:106171. [PMID: 33038503 DOI: 10.1016/j.cct.2020.106171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Agrawal G, Hamblin H, Clancy A, Borody T. Anti-Mycobacterial Antibiotic Therapy Induces Remission in Active Paediatric Crohn's Disease. Microorganisms. 2020;8:1112. [PMID: 32722117 DOI: 10.3390/microorganisms8081112] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 24 |
Ceballos D. Sleep Quality, Quality of Life, and Patient-Reported Outcomes. Inflamm Bowel Dis 2020;26:1260. [PMID: 31820792 DOI: 10.1093/ibd/izz277] [Reference Citation Analysis]
|
| 25 |
Obando C, Ding Z, Muser E, Vaidya N, Qiang W, Sun X, Wang H, Mallampati R, Xie L. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States. Adv Ther 2020;37:2127-43. [PMID: 32193810 DOI: 10.1007/s12325-020-01276-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 26 |
Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn's disease. Nat Rev Dis Primers 2020;6:22. [PMID: 32242028 DOI: 10.1038/s41572-020-0156-2] [Cited by in Crossref: 207] [Cited by in F6Publishing: 211] [Article Influence: 69.0] [Reference Citation Analysis]
|
| 27 |
Radford SJ, McGing J, Czuber-Dochan W, Moran G. Systematic review: the impact of inflammatory bowel disease-related fatigue on health-related quality of life. Frontline Gastroenterol 2021;12:11-21. [PMID: 33489066 DOI: 10.1136/flgastro-2019-101355] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 28 |
Chen H, Shi J, Pan Y, Zhang Z, Fang H, Chen Y, Chen W, Cao Q. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China. Adv Ther 2020;37:431-49. [PMID: 31797196 DOI: 10.1007/s12325-019-01150-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 29 |
Ferreira TMR, Albuquerque A, Cancela Penna FG, Macedo Rosa R, Correia MITD, Barbosa AJA, Salles Cunha A, Ferrari MLA. Effect of Oral Nutrition Supplements and TGF-β2 on Nutrition and Inflammatory Patterns in Patients With Active Crohn's Disease. Nutr Clin Pract 2020;35:885-93. [PMID: 31840323 DOI: 10.1002/ncp.10448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 30 |
Taylor K, Scruggs PW, Balemba OB, Wiest MM, Vella CA. Physical Activity, Sitting, Quality of Life, and Resilience in Inflammatory Bowel Disease. Journal of Clinical Exercise Physiology 2019;8:121-130. [DOI: 10.31189/2165-6193-8.4.121] [Reference Citation Analysis]
|
| 31 |
Bolin K, Hertervig E, Louis E. The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease. J Crohns Colitis 2019;13:1323-33. [PMID: 30893421 DOI: 10.1093/ecco-jcc/jjz063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 32 |
Van Wilder L, Rammant E, Clays E, Devleesschauwer B, Pauwels N, De Smedt D. A comprehensive catalogue of EQ-5D scores in chronic disease: results of a systematic review. Qual Life Res 2019;28:3153-61. [PMID: 31531840 DOI: 10.1007/s11136-019-02300-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 33 |
Schütz L, Radke M, Menzel S, Däbritz J. Long-term implications of structured transition of adolescents with inflammatory bowel disease into adult health care: a retrospective study. BMC Gastroenterol 2019;19:128. [PMID: 31324228 DOI: 10.1186/s12876-019-1046-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 34 |
Long MD, Martin CF, Chen W, Luo M. Changes in Patient-Reported Outcomes With Vedolizumab Therapy in Patients With Inflammatory Bowel Diseases (IBD): Results From the IBD Partners Patient Powered Research Network. Crohn's & Colitis 360 2019;1. [DOI: 10.1093/crocol/otz020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 35 |
Norton JC, Slawinski PR, Lay HS, Martin JW, Cox BF, Cummins G, Desmulliez MPY, Clutton RE, Obstein KL, Cochran S, Valdastri P. Intelligent magnetic manipulation for gastrointestinal ultrasound. Sci Robot 2019;4:eaav7725. [PMID: 31380501 DOI: 10.1126/scirobotics.aav7725] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 36 |
Armuzzi A, Riegler G, Furfaro F, Baldoni M, Costa F, Fortuna M, Iaquinto G, Paese P, Papi C, Bossa F, Tontini GE, Di Fino S, Gualberti G, Merolla R, Rizzello F. Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn's disease. Dig Liver Dis 2019;51:804-11. [PMID: 30685416 DOI: 10.1016/j.dld.2018.12.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 37 |
Czuber-Dochan W, Morgan M, Hughes LD, Lomer MCE, Lindsay JO, Whelan K. Perceptions and psychosocial impact of food, nutrition, eating and drinking in people with inflammatory bowel disease: a qualitative investigation of food-related quality of life. J Hum Nutr Diet 2020;33:115-27. [PMID: 31131484 DOI: 10.1111/jhn.12668] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 38 |
Ghosh S, Bressler B, Petkau J, Thakkar RB, Wang S, Skup M, Chao J, Panaccione R, Schreiber S. Healthcare Providers Underestimate Patients' Glucocorticoid Use in Crohn's Disease. Dig Dis Sci 2019;64:1142-9. [PMID: 30659472 DOI: 10.1007/s10620-018-5419-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 39 |
Worbes-Cerezo M, Nafees B, Lloyd A, Gallop K, Ladha I, Kerr C. Disutility Study for Adult Patients with Moderate to Severe Crohn's Disease. J Health Econ Outcomes Res 2019;6:47-60. [PMID: 32685579 DOI: 10.36469/9685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 40 |
Sarwan N, Jurawan R, Singh R, Chattu VK. An Exploratory Study of Inflammatory Bowel Disease and the Psychosocial Factors Affecting Health-Related Quality of Life. Med Sci (Basel) 2019;7:E18. [PMID: 30691020 DOI: 10.3390/medsci7020018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 41 |
Kim ES, Kwon KT, Kim SK, Kim M, Lee HS, Jang BI, Kim KO, Kim EY, Lee YJ, Hong SJ, Yang CH, Kang B, Choe BH; Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD). Impact of Education on School Nurses' Knowledge of Inflammatory Bowel Disease. Gut Liver 2019;13:48-53. [PMID: 30037169 DOI: 10.5009/gnl18139] [Reference Citation Analysis]
|
| 42 |
Kim S, Park S, Kang Y, Kim JE, Kang B, Choe BH, Lee YJ, Park JH, Yang HR, Lee SH, Kim KM, Ryoo E, Tchah H, Shim JO, Koh H. Can We Estimate Quality of Life in Pediatric Inflammatory Bowel Disease Patients? An Asian Multicenter Study. J Pediatr Gastroenterol Nutr 2019;68:45-9. [PMID: 30052570 DOI: 10.1097/MPG.0000000000002119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 43 |
Martínez-pérez A, Payá-llorente C, García-lozano A. Socioeconomic Impact of Emergency Therapies for Colorectal Cancer. Emergency Surgical Management of Colorectal Cancer 2019. [DOI: 10.1007/978-3-030-06225-5_3] [Reference Citation Analysis]
|
| 44 |
Hood MM, Wilson R, Gorenz A, Jedel S, Raeisi S, Hobfoll S, Keshavarzian A. Sleep Quality in Ulcerative Colitis: Associations with Inflammation, Psychological Distress, and Quality of Life. Int J Behav Med 2018;25:517-25. [PMID: 30159665 DOI: 10.1007/s12529-018-9745-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 45 |
Espí-López GV, Inglés M, Soliva-Cazabán I, Serra-Añó P. Effect of the soft-tissue techniques in the quality of life in patients with Crohn's disease: A randomized controlled trial. Medicine (Baltimore) 2018;97:e13811. [PMID: 30572544 DOI: 10.1097/MD.0000000000013811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 46 |
Min Ho PY, Hu W, Lee YY, Gao C, Tan YZ, Cheen HH, Wee HL, Lim TG, Ong WC. Health-related quality of life of patients with inflammatory bowel disease in Singapore. Intest Res 2019;17:107-18. [PMID: 30419638 DOI: 10.5217/ir.2018.00099] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 47 |
Tajiri H, Motoya S, Kinjo F, Maemoto A, Matsumoto T, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T. Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. PLoS One 2018;13:e0201956. [PMID: 30114224 DOI: 10.1371/journal.pone.0201956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 48 |
Ballou S, Hirsch W, Singh P, Rangan V, Nee J, Iturrino J, Sommers T, Zubiago J, Sengupta N, Bollom A, Jones M, Moss AC, Flier SN, Cheifetz AS, Lembo A. Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014. Aliment Pharmacol Ther 2018;47:913-21. [PMID: 29411411 DOI: 10.1111/apt.14551] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 49 |
Scaringi S, Di Bella A, Boni L, Giudici F, Di Martino C, Zambonin D, Ficari F. New perspectives on the long-term outcome of segmental colectomy for Crohn's colitis: an observational study on 200 patients. Int J Colorectal Dis 2018;33:479-85. [PMID: 29511841 DOI: 10.1007/s00384-018-2998-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 50 |
Kunovsky L, Mitas L, Marek F, Dolina J, Poredska K, Kucerova L, Benesova K, Kala Z. Impact of surgery on quality of life in Crohn's disease patients: final results of Czech cohort. Vnitř Lék 2018;64:347-54. [DOI: 10.36290/vnl.2018.052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 51 |
Kappelman MD, Lange A, Randell RL, Basta PV, Sandler RS, Laugesen K, Byrjalsen A, Christensen T, Frøslev T, Erichsen R. Feasibility of salivary DNA collection in a population-based case-control study: a pilot study of pediatric Crohn's disease. Clin Epidemiol 2018;10:215-22. [PMID: 29535554 DOI: 10.2147/CLEP.S143322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 52 |
Freeman K, Connock M, Auguste P, Taylor-Phillips S, Mistry H, Shyangdan D, Court R, Arasaradnam R, Sutcliffe P, Clarke A. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. Health Technol Assess 2016;20:1-288. [PMID: 27845027 DOI: 10.3310/hta20830] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 53 |
Pavurala RB, Johnson A, Hinton A, Krishna SG, Afzali A, Zhang C. Appendectomy for Appendicitis Has Worse Hospital Outcomes in Inflammatory Bowel Disease Patients. JBM 2018;06:23-35. [DOI: 10.4236/jbm.2018.65004] [Reference Citation Analysis]
|
| 54 |
Engels M, Cross RK, Long MD. Exercise in patients with inflammatory bowel diseases: current perspectives. Clin Exp Gastroenterol. 2018;11:1-11. [PMID: 29317842 DOI: 10.2147/ceg.s120816] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 55 |
Yun SM, Park SK, Lim HS. Influence of pilates training on the quality of life of chronic stroke patients. J Phys Ther Sci 2017;29:1830-5. [PMID: 29184300 DOI: 10.1589/jpts.29.1830] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 56 |
Alexakis C, Kumar S, Saxena S, Pollok R. Systematic review with meta-analysis: the impact of a depressive state on disease course in adult inflammatory bowel disease. Aliment Pharmacol Ther 2017;46:225-35. [PMID: 28573652 DOI: 10.1111/apt.14171] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 57 |
Kostić M, Djakovic L, Šujić R, Godman B, Janković SM. Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications. Appl Health Econ Health Policy 2017;15:85-93. [PMID: 27587010 DOI: 10.1007/s40258-016-0272-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 58 |
Conway G, Velonias G, Andrews E, Garber JJ, Yajnik V, Ananthakrishnan AN. The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;45:814-23. [PMID: 28105709 DOI: 10.1111/apt.13940] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 59 |
Zeitz J, Fournier N, Labenz C, Biedermann L, Frei P, Misselwitz B, Scharl S, Vavricka SR, Sulz MC, Fried M, Rogler G, Scharl M. Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Intest Dis. 2017;1:172-181. [PMID: 29922674 DOI: 10.1159/000458144] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 60 |
Chouliaras G, Margoni D, Dimakou K, Fessatou S, Panayiotou I, Roma-Giannikou E. Disease impact on the quality of life of children with inflammatory bowel disease. World J Gastroenterol 2017; 23(6): 1067-1075 [PMID: 28246481 DOI: 10.3748/wjg.v23.i6.1067] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 61 |
Velonias G, Conway G, Andrews E, Garber JJ, Khalili H, Yajnik V, Ananthakrishnan AN. Older Age- and Health-related Quality of Life in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2017;23:283-8. [PMID: 28079625 DOI: 10.1097/MIB.0000000000001008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 62 |
Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, Klopocka M, Goldis A, Wisniewska-Jarosinska M, Baranovsky A, Sike R, Stoyanova K, Tasset C, Van der Aa A, Harrison P. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 2017;389:266-75. [PMID: 27988142 DOI: 10.1016/S0140-6736(16)32537-5] [Cited by in Crossref: 280] [Cited by in F6Publishing: 272] [Article Influence: 46.7] [Reference Citation Analysis]
|
| 63 |
Tsoukka M, Jelastopulu E, Lavranos G, Charalambous G. Estimation of quality of life in Cypriot patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(1): 121-126 [PMID: 28104987 DOI: 10.3748/wjg.v23.i1.121] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 64 |
Ueno F, Nakayama Y, Hagiwara E, Kurimoto S, Hibi T. Impact of inflammatory bowel disease on Japanese patients' quality of life: results of a patient questionnaire survey. J Gastroenterol 2017;52:555-67. [PMID: 27470433 DOI: 10.1007/s00535-016-1241-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 65 |
Carlsen K, Munkholm P, Burisch J. Evaluation of Quality of Life in Crohn’s Disease and Ulcerative Colitis: What Is Health-Related Quality of Life? Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_25] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 66 |
Holdam AS, Bager P, Dahlerup JF. Biological therapy increases the health-related quality of life in patients with inflammatory bowel disease in a clinical setting. Scand J Gastroenterol 2016;51:706-11. [PMID: 26794211 DOI: 10.3109/00365521.2015.1136352] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 67 |
Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years - United States, 2015. MMWR Morb Mortal Wkly Rep 2016;65:1166-9. [PMID: 27787492 DOI: 10.15585/mmwr.mm6542a3] [Cited by in Crossref: 339] [Cited by in F6Publishing: 349] [Article Influence: 48.4] [Reference Citation Analysis]
|
| 68 |
Wang SL, Zhao SB, Fang J, Ma D, Fu HY, Li ZS, Bai Y. Role of stress and intestinal barrier dysfunction in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2016; 24(21): 3248-3254 [DOI: 10.11569/wcjd.v24.i21.3248] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 69 |
Gecse KB, Sebastian S, Hertogh Gd, Yassin NA, Kotze PG, Reinisch W, Spinelli A, Koutroubakis IE, Katsanos KH, Hart A, van den Brink GR, Rogler G, Bemelman WA. Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs. J Crohns Colitis 2016;10:758-65. [PMID: 26826183 DOI: 10.1093/ecco-jcc/jjw039] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 70 |
Ganz ML, Sugarman R, Wang R, Hansen BB, Håkan-Bloch J. The Economic and Health-related Impact of Crohn's Disease in the United States: Evidence from a Nationally Representative Survey. Inflamm Bowel Dis 2016;22:1032-41. [PMID: 26974852 DOI: 10.1097/MIB.0000000000000742] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 71 |
Hughes LD, King L, Morgan M, Ayis S, Direkze N, Lomer MC, Lindsay JO, Whelan K. Food-related Quality of Life in Inflammatory Bowel Disease: Development and Validation of a Questionnaire. J Crohns Colitis 2016;10:194-201. [PMID: 26507859 DOI: 10.1093/ecco-jcc/jjv192] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 72 |
Chung AE, Sandler RS, Long MD, Ahrens S, Burris JL, Martin CF, Anton K, Robb A, Caruso TP, Jaeger EL, Chen W, Clark M, Myers K, Dobes A, Kappelman MD. Harnessing person-generated health data to accelerate patient-centered outcomes research: the Crohn's and Colitis Foundation of America PCORnet Patient Powered Research Network (CCFA Partners). J Am Med Inform Assoc 2016;23:485-90. [PMID: 26911821 DOI: 10.1093/jamia/ocv191] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 73 |
Yanartas O, Kani HT, Bicakci E, Kilic I, Banzragch M, Acikel C, Atug O, Kuscu K, Imeryuz N, Akin H. The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease. Neuropsychiatr Dis Treat 2016;12:673-83. [PMID: 27069364 DOI: 10.2147/NDT.S106039] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 74 |
Kaminski J. From Community Analysis to Prototype: Creating an Online Matchmaker for Inflammatory Bowel Disease Patients. Boundaryless Hospital 2016. [DOI: 10.1007/978-3-662-49012-9_17] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 75 |
Tsertsvadze A, Gurung T, Court R, Clarke A, Sutcliffe P. Clinical effectiveness and cost-effectiveness of elemental nutrition for the maintenance of remission in Crohn's disease: a systematic review and meta-analysis. Health Technol Assess 2015;19:1-138. [PMID: 25831484 DOI: 10.3310/hta19260] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 76 |
Greenberg D, Schwartz D, Vardi H, Friger M, Sarid O, Slonim-Nevo V, Odes S; Israeli IBD Research Nucleus [IIRN]. Health-Related Utility Weights in a Cohort of Real-World Crohn's Disease Patients. J Crohns Colitis 2015;9:1138-45. [PMID: 26374662 DOI: 10.1093/ecco-jcc/jjv167] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 77 |
Feagan BG, Sandborn WJ, D'Haens G, Lee SD, Allez M, Fedorak RN, Seidler U, Vermeire S, Lawrance IC, Maroney AC, Jurgensen CH, Heath A, Chang DJ. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. Aliment Pharmacol Ther 2015;42:1170-81. [PMID: 26400458 DOI: 10.1111/apt.13398] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 78 |
Vitale DS, Greenley RN, Lerner DG, Mavis AM, Werlin SL. Adherence to Infliximab Treatment in a Pediatric Inflammatory Bowel Disease Cohort. J Pediatr Gastroenterol Nutr 2015;61:408-10. [PMID: 25885878 DOI: 10.1097/MPG.0000000000000817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 79 |
D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG; Laquinimod for Crohn's Disease Investigators. A phase II study of laquinimod in Crohn's disease. Gut 2015;64:1227-35. [PMID: 25281416 DOI: 10.1136/gutjnl-2014-307118] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 80 |
Chandar AK, Singh S, Murad MH, Peyrin-Biroulet L, Loftus EV Jr. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2015;21:1695-708. [PMID: 25856769 DOI: 10.1097/MIB.0000000000000373] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 81 |
Saro C, Ceballos D, Muñoz F, De la Coba C, Aguilar MD, Lázaro P, Iglesias-Flores E, Barreiro-de Acosta M, Hernández-Durán MD, Barrio J, Riestra S, Fernández Salazar L; EFICADEC Researchers Group. Resources Utilization and Costs the Year Before and After Starting Treatment with Adalimumab in Crohn's Disease Patients. Inflamm Bowel Dis 2015;21:1631-40. [PMID: 25961910 DOI: 10.1097/MIB.0000000000000413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 82 |
Keeton RL, Mikocka-Walus A, Andrews JM. Concerns and worries in people living with inflammatory bowel disease (IBD): A mixed methods study. J Psychosom Res 2015;78:573-8. [PMID: 25543858 DOI: 10.1016/j.jpsychores.2014.12.004] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 83 |
Matsumoto T, Yanai S, Toya Y, Ueno M, Nakamura S. Internet-orientated Assessment of QOL and Actual Treatment Status in Japanese Patients with Inflammatory Bowel Disease: The 3I survey. J Crohns Colitis 2015;9:477-82. [PMID: 25814388 DOI: 10.1093/ecco-jcc/jjv052] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 84 |
Gater A, Kitchen H, Heron L, Pollard C, Håkan-Bloch J, Højbjerre L, Hansen BB, Strandberg-Larsen M. Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation. Expert Rev Pharmacoecon Outcomes Res 2015;15:643-56. [PMID: 25985850 DOI: 10.1586/14737167.2015.1045883] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 85 |
Wright EK, Kamm MA. Impact of drug therapy and surgery on quality of life in Crohn's disease: a systematic review. Inflamm Bowel Dis 2015;21:1187-94. [PMID: 25895008 DOI: 10.1097/MIB.0000000000000271] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 86 |
Martin TD, Chan SS, Hart AR. Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature. Dig Dis Sci 2015;60:1396-405. [PMID: 25407806 DOI: 10.1007/s10620-014-3437-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 87 |
Atreja A, Khan S, Rogers JD, Otobo E, Patel NP, Ullman T, Colombel JF, Moore S, Sands BE; HealthPROMISE Consortium Group. Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial. JMIR Res Protoc. 2015;4:e23. [PMID: 25693610 DOI: 10.2196/resprot.4042] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 88 |
Magalhães J, Castro FD, Carvalho PB, Moreira MJ, Cotter J. Quality of life in patients with inflammatory bowel disease: importance of clinical, demographic and psychosocial factors. Arq Gastroenterol 2014;51:192-7. [PMID: 25296078 DOI: 10.1590/s0004-28032014000300005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 89 |
Magalhães J, Castro FD, Carvalho PB, Machado JF, Leite S, Moreira MJ, Cotter J. Disability in Inflammatory Bowel Disease: Translation to Portuguese and Validation of the "Inflammatory Bowel Disease - Disability Score". GE Port J Gastroenterol 2015;22:4-14. [PMID: 28868362 DOI: 10.1016/j.jpge.2014.10.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 90 |
Bellolio-roth F, Mcleod RS. Quality of Life in Patients with Crohn’s Disease. Crohn’s Disease 2015. [DOI: 10.1007/978-3-319-14181-7_23] [Reference Citation Analysis]
|
| 91 |
Gilet H, Arnould B, Fofana F, Clerson P, Colombel JF, D'Hondt O, Faure P, Hagège H, Nachury M, Nahon S, Tucat G, Vandromme L, Cazala-Telinge I, Thibout E. Measuring patients' satisfaction with their anti-TNF treatment in severe Crohn's disease: scoring and psychometric validation of the Satisfaction for PAtients in Crohn's diseasE Questionnaire (SPACE-Q(©)). Patient Prefer Adherence 2014;8:1671-81. [PMID: 25525343 DOI: 10.2147/PPA.S72004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 92 |
Hall B, Holleran G, McNamara D. Small bowel Crohn's disease: an emerging disease phenotype? Dig Dis 2015;33:42-51. [PMID: 25531496 DOI: 10.1159/000366047] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 93 |
Watanabe M, Hibi T, Mostafa NM, Chao J, Arora V, Camez A, Petersson J, Thakkar R. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease. J Crohns Colitis 2014;8:1407-16. [PMID: 24874893 DOI: 10.1016/j.crohns.2014.04.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 94 |
Atreja A, Patel SS, Boules M, Putka B, Rizk M. Automated recall system for colonoscopy: a generalizable informatics solution for procedures requiring timely follow-up. Gastrointest Endosc 2014;80:684-8. [PMID: 24818546 DOI: 10.1016/j.gie.2014.03.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 95 |
Bodger K, Ormerod C, Shackcloth D, Harrison M; IBD Control Collaborative. Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut 2014;63:1092-102. [PMID: 24107590 DOI: 10.1136/gutjnl-2013-305600] [Cited by in Crossref: 103] [Cited by in F6Publishing: 102] [Article Influence: 11.4] [Reference Citation Analysis]
|
| 96 |
Caplan RA, Maunder RG, Stempak JM, Silverberg MS, Hart TL. Attachment, childhood abuse, and IBD-related quality of life and disease activity outcomes. Inflamm Bowel Dis 2014;20:909-15. [PMID: 24651585 DOI: 10.1097/MIB.0000000000000015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 97 |
Rubin DT, Mody R, Davis KL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther 2014;39:1143-55. [PMID: 24697826 DOI: 10.1111/apt.12727] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 98 |
Gandhi S, Jedel S, Hood MM, Mutlu E, Swanson G, Keshavarzian A. The relationship between coping, health competence and patient participation among patients with inactive inflammatory bowel disease. J Crohns Colitis 2014;8:401-8. [PMID: 24230968 DOI: 10.1016/j.crohns.2013.10.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 99 |
Sherman M, Tsynman DN, Kim A, Arora J, Pietras T, Messing S, St Hilaire L, Yoon S, Decross A, Shah A, Saubermann L. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy. J Dig Dis 2014;15:174-9. [PMID: 24373601 DOI: 10.1111/1751-2980.12125] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 100 |
van der Have M, van der Aalst KS, Kaptein AA, Leenders M, Siersema PD, Oldenburg B, Fidder HH. Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis 2014;8:93-106. [PMID: 23746864 DOI: 10.1016/j.crohns.2013.04.007] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 10.1] [Reference Citation Analysis]
|
| 101 |
Sandborn WJ, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials. J Crohns Colitis 2013;7:958-67. [PMID: 23517933 DOI: 10.1016/j.crohns.2013.02.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 102 |
Buckley JP, Kappelman MD, Allen JK, Van Meter SA, Cook SF. The burden of comedication among patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2725-36. [PMID: 24216689 DOI: 10.1097/01.MIB.0000435442.07237.a4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 103 |
Carroll IM, Maharshak N. Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications. World J Gastroenterol 2013; 19(43): 7531-7543 [PMID: 24431894 DOI: 10.3748/wjg.v19.i43.7531] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 104 |
Haberer LJ, Hacquoil K, Ino H, Sakamoto T, Kanemoto N, Mcsherry I, Hirama T. Single‐Dose Pharmacokinetics of the CCR9 Receptor Antagonist Vercirnon in Healthy US and Japanese Subjects. CPDD 2013;2:387-93. [DOI: 10.1002/cpdd.41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 105 |
Casellas F, Ginard D, Vera I, Torrejón A; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Satisfaction of health care professionals managing patients with inflammatory bowel disease. J Crohns Colitis 2013;7:e249-55. [PMID: 23138131 DOI: 10.1016/j.crohns.2012.10.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 106 |
Guo Z, Wu R, Zhu W, Gong J, Zhang W, Li Y, Gu L, Li N, Li J. Effect of exclusive enteral nutrition on health-related quality of life for adults with active Crohn’s disease. Nutr Clin Pract. 2013;28:499-505. [PMID: 23851180 DOI: 10.1177/0884533613487218] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 107 |
Maharshak N, Packey CD, Ellermann M, Manick S, Siddle JP, Huh EY, Plevy S, Sartor RB, Carroll IM. Altered enteric microbiota ecology in interleukin 10-deficient mice during development and progression of intestinal inflammation. Gut Microbes 2013;4:316-24. [PMID: 23822920 DOI: 10.4161/gmic.25486] [Cited by in Crossref: 97] [Cited by in F6Publishing: 97] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 108 |
Novak KL, Wilson SR. The Role of Ultrasound in the Evaluation of Inflammatory Bowel Disease. Seminars in Roentgenology 2013;48:224-33. [DOI: 10.1053/j.ro.2013.03.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 109 |
Beunk L, Verwoerd A, van Overveld FJ, Rijkers GT. Role of mast cells in mucosal diseases: current concepts and strategies for treatment. Expert Rev Clin Immunol. 2013;9:53-63. [PMID: 23256764 DOI: 10.1586/eci.12.82] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 110 |
Laguette V, Apostolidis T, Dany L, Bellon N, Grimaud J, Lagouanelle-simeoni M. Quality of life and time perspective in inflammatory bowel disease patients. Qual Life Res 2013;22:2721-36. [DOI: 10.1007/s11136-013-0399-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 111 |
Kim ES, Cho KB, Park KS, Jang BI, Kim KO, Jeon SW, Jung MK, Kim EY, Yang CH; Daegukyungbook Gastrointestinal Study Group (DGSG). Predictive factors of impaired quality of life in Korean patients with inactive inflammatory bowel disease: association with functional gastrointestinal disorders and mood disorders. J Clin Gastroenterol 2013;47:e38-44. [PMID: 23090047 DOI: 10.1097/MCG.0b013e318266fff5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 112 |
Seidelin JB, Coskun M, Nielsen OH. Mucosal healing in ulcerative colitis: pathophysiology and pharmacology. Adv Clin Chem 2013;59:101-23. [PMID: 23461134 DOI: 10.1016/b978-0-12-405211-6.00004-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 113 |
Jedel S, Merriman P, Hoffman A, Swanson B, Fogg LF, Keshavarzian A. Relationship of Mindfulness, Quality of Life, and Psychiatric Symptoms Among Patients with Ulcerative Colitis. Mindfulness 2013;4:296-300. [DOI: 10.1007/s12671-012-0128-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 114 |
Achleitner U, Coenen M, Colombel JF, Peyrin-Biroulet L, Sahakyan N, Cieza A. Identification of areas of functioning and disability addressed in inflammatory bowel disease-specific patient reported outcome measures. J Crohns Colitis 2012;6:507-17. [PMID: 22398049 DOI: 10.1016/j.crohns.2011.11.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 115 |
Mizrahi MC, Reicher-Atir R, Levy S, Haramati S, Wengrower D, Israeli E, Goldin E. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychol Health. 2012;27:1463-1479. [PMID: 22646975 DOI: 10.1080/08870446.2012.691169] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 116 |
Keefer L, Doerfler B, Artz C. Optimizing management of Crohn's disease within a project management framework: results of a pilot study. Inflamm Bowel Dis 2012;18:254-60. [PMID: 21351218 DOI: 10.1002/ibd.21679] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 117 |
Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Early versus late surgery in patients with intestinal Behçet disease. Dis Colon Rectum 2012;55:65-71. [PMID: 22156869 DOI: 10.1097/DCR.0b013e318238b57e] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 118 |
Munkholm P, Pedersen N. Evaluation of Quality of Life in Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2012. [DOI: 10.1007/978-1-4614-0998-4_25] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 119 |
Haapamäki J, Roine RP, Sintonen H, Kolho KL. Health-related quality of life in paediatric patients with inflammatory bowel disease related to disease activity. J Paediatr Child Health 2011;47:832-7. [PMID: 21435075 DOI: 10.1111/j.1440-1754.2011.02034.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 120 |
Panaccione R, Loftus EV Jr, Binion D, McHugh K, Alam S, Chen N, Guerette B, Mulani P, Chao J. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol 2011;25:419-25. [PMID: 21912766 DOI: 10.1155/2011/724813] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 121 |
Marant C, Arnould B, Marrel A, Spizak C, Colombel JF, Faure P, Hagege H, Lemann M, Nahon S, Tucat G, Vandromme L, Thibout E, Goldfarb G. Assessing patients' satisfaction with anti-TNFα treatment in Crohn's disease: qualitative steps of the development of a new questionnaire. Clin Exp Gastroenterol 2011;4:173-80. [PMID: 21904463 DOI: 10.2147/CEG.S18585] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 122 |
Étienne A, Dupuis G. Maladie de Crohn et qualité de vie : des pistes d’intervention. Perspectives Psy 2011;50:246-255. [DOI: 10.1051/ppsy/2011503246] [Reference Citation Analysis]
|
| 123 |
Feagan BG, Hanauer SB, Coteur G, Schreiber S. Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther 2011;33:1143-51. [PMID: 21443536 DOI: 10.1111/j.1365-2036.2011.04636.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 124 |
Kappelman MD, Galanko JA, Porter CQ, Sandler RS. Risk of diagnosed fractures in children with inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:1125-30. [PMID: 20872833 DOI: 10.1002/ibd.21472] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 125 |
Cunningham MF, Docherty NG, Coffey JC, Burke JP, O’Connell PR. Postsurgical recurrence of ileal Crohn’s disease: an update on risk factors and intervention points to a central role for impaired host-microflora homeostasis. World J Surg. 2010;34:1615-1626. [PMID: 20195604 DOI: 10.1007/s00268-010-0504-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 126 |
Zheng CF, Xu JH, Huang Y, Leung YK. Treatment of pediatric refractory Crohn’s disease with thalidomide. World J Gastroenterol 2011; 17(10): 1286-1291 [PMID: 21455327 DOI: 10.3748/wjg.v17.i10.1286] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 127 |
Lesage AC, Hagège H, Tucat G, Gendre JP. Results of a national survey on quality of life in inflammatory bowel diseases. Clin Res Hepatol Gastroenterol 2011;35:117-24. [PMID: 21036501 DOI: 10.1016/j.gcb.2009.08.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 128 |
Kappelman MD, Porter CQ, Galanko JA, Rifas-Shiman SL, Ollendorf DA, Sandler RS, Finkelstein JA. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:62-8. [PMID: 20564532 DOI: 10.1002/ibd.21371] [Cited by in Crossref: 90] [Cited by in F6Publishing: 64] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 129 |
Kappelman MD, Crandall WV, Colletti RB, Goudie A, Leibowitz IH, Duffy L, Milov DE, Kim SC, Schoen BT, Patel AS, Grunow J, Larry E, Fairbrother G, Margolis P. Short pediatric Crohn's disease activity index for quality improvement and observational research. Inflamm Bowel Dis 2011;17:112-7. [PMID: 20812330 DOI: 10.1002/ibd.21452] [Cited by in Crossref: 108] [Cited by in F6Publishing: 62] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 130 |
Shah B, Tinsley A, Ullman T. Quality of Care in Inflammatory Bowel Disease. Curr Gastroenterol Rep 2011;13:87-94. [DOI: 10.1007/s11894-010-0155-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 131 |
Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010;32:1228-39. [PMID: 20955442 DOI: 10.1111/j.1365-2036.2010.04466.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 97] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 132 |
Umanskiy K, Fichera A. Health related quality of life in inflammatory bowel disease: The impact of surgical therapy. World J Gastroenterol 2010; 16(40): 5024-5034 [PMID: 20976838 DOI: 10.3748/wjg.v16.i40.5024] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 133 |
Kiebles JL, Doerfler B, Keefer L. Preliminary evidence supporting a framework of psychological adjustment to inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1685-95. [PMID: 20155849 DOI: 10.1002/ibd.21215] [Cited by in Crossref: 89] [Cited by in F6Publishing: 67] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 134 |
Arai R. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease. Postgrad Med. 2010;122:177-185. [PMID: 20675980 DOI: 10.3810/pgm.2010.07.2184] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 135 |
Hill R, Lewindon P, Muir R, Grangé I, Connor F, Ee L, Withers G, Cleghorn G, Davies P. Quality of life in children with Crohn disease. J Pediatr Gastroenterol Nutr 2010;51:35-40. [PMID: 20410845 DOI: 10.1097/MPG.0b013e3181c2c0ef] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 136 |
Lichtenstein GR, Waters HC, Kelly J, Mcdonald SS, Zanutto EL, Hendricks D, Rahman MI. Assessing Drug Treatment Preferences of Patients with Crohnʼs Disease: A Conjoint Analysis. The Patient: Patient-Centered Outcomes Research 2010;3:113-23. [DOI: 10.2165/11314880-000000000-00000] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 137 |
Strauch U, Schölmerich J. Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs 2010;15:309-22. [PMID: 20402560 DOI: 10.1517/14728214.2010.480972] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 138 |
Wilcox AR, Dragnev MC, Darcey CJ, Siegel CA. A new tool to measure the burden of Crohn's disease and its treatment: do patient and physician perceptions match? Inflamm Bowel Dis 2010;16:645-50. [PMID: 19714751 DOI: 10.1002/ibd.21094] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 139 |
Ananthakrishnan AN, Beaulieu DB, Ulitsky A, Zadvornova Y, Skaros S, Johnson K, Naik A, Perera L, Issa M, Binion DG, Saeian K. Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease? Inflamm Bowel Dis 2010;16:494-500. [PMID: 19637332 DOI: 10.1002/ibd.21051] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 140 |
Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J; European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010;4:63-101. [PMID: 21122490 DOI: 10.1016/j.crohns.2009.09.009] [Cited by in Crossref: 569] [Cited by in F6Publishing: 590] [Article Influence: 43.8] [Reference Citation Analysis]
|
| 141 |
Frattini JC, Marcet JE. Quality of Life Issues and Rectal Cancer. Coloproctology 2010. [DOI: 10.1007/978-1-84882-756-1_6] [Reference Citation Analysis]
|
| 142 |
Kappelman MD, Palmer L, Boyle BM, Rubin DT. Quality of care in inflammatory bowel disease: a review and discussion. Inflamm Bowel Dis 2010;16:125-33. [PMID: 19572335 DOI: 10.1002/ibd.21028] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 143 |
Bin CM, Flores C, Alvares-da-Silva MR, Francesconi CF. Comparison between handgrip strength, subjective global assessment, anthropometry, and biochemical markers in assessing nutritional status of patients with Crohn's disease in clinical remission. Dig Dis Sci 2010;55:137-44. [PMID: 19229617 DOI: 10.1007/s10620-008-0692-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 144 |
Wexner SD, Frattini JC. Quality of Life in Crohn’s Disease. Handbook of Disease Burdens and Quality of Life Measures 2010. [DOI: 10.1007/978-0-387-78665-0_127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 145 |
Pérez CA. Prescription of physical exercise in Crohn's disease. J Crohns Colitis 2009;3:225-31. [PMID: 21172280 DOI: 10.1016/j.crohns.2009.08.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 146 |
Michetti P, Stelle M, Juillerat P, Gassull M, Heil FJ, Stange E, Mottet C, Gonvers JJ, Pittet V, Vader JP, Froehlich F, Felley C; EPACT II Study Group. Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis 2009;3:232-40. [PMID: 21172281 DOI: 10.1016/j.crohns.2009.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 147 |
Graff LA, Walker JR, Clara I, Lix L, Miller N, Rogala L, Rawsthorne P, Bernstein CN. Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol 2009;104:2959-69. [PMID: 19755973 DOI: 10.1038/ajg.2009.529] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 148 |
Taxonera C, Rodrigo L, Casellas F, Calvet X, Gómez-Camacho F, Ginard D, Castro M, Castro L, Ponce M, Martínez-Montiel P, Ricart E, Gisbert JP, López-San Román A, Morales JM, Casado MA. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. J Clin Gastroenterol 2009;43:950-6. [PMID: 19448569 DOI: 10.1097/MCG.0b013e3181986917] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 149 |
Ng SC, Plamondon S, Gupta A, Burling D, Kamm MA. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas. Aliment Pharmacol Ther 2009;30:757-66. [PMID: 19575762 DOI: 10.1111/j.1365-2036.2009.04088.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 150 |
Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol 2009;104:1976-83. [PMID: 19471252 DOI: 10.1038/ajg.2009.199] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 151 |
Sadowski DC, Bernstein CN, Bitton A, Croitoru K, Fedorak RN, Griffiths A; CAG Crohn's Consensus Group. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202. [PMID: 19319383 DOI: 10.1155/2009/201430] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 152 |
Papadakis KA. Crohn's disease: Adalimumab improves quality of life. Nat Rev Gastroenterol Hepatol 2009;6:200-1. [PMID: 19347008 DOI: 10.1038/nrgastro.2009.39] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 153 |
Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, Finkelstein JA. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907-13. [PMID: 18854185 DOI: 10.1053/j.gastro.2008.09.012] [Cited by in Crossref: 469] [Cited by in F6Publishing: 497] [Article Influence: 31.3] [Reference Citation Analysis]
|
| 154 |
Irvine EJ, Yeh CH, Ramsey D, Stirling AL, Higgins PD. The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis. Aliment Pharmacol Ther 2008;28:1278-86. [PMID: 18808446 DOI: 10.1111/j.1365-2036.2008.03854.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 155 |
Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008;103:3132-41. [PMID: 18853973 DOI: 10.1111/j.1572-0241.2008.02175.x] [Cited by in Crossref: 144] [Cited by in F6Publishing: 142] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 156 |
Michetti P, Juillerat P, Mottet C, Pittet V, Gonvers JJ, Vader JP, Froehlich F, Felley C. Mild-to-moderate active luminal Crohn's disease. Digestion 2007;76:92-8. [PMID: 18239399 DOI: 10.1159/000111022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 157 |
Rutgeerts P, Schreiber S, Feagan B, Keininger DL, O'Neil L, Fedorak RN; CDP870 Crohn's Disease Study Group. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008;23:289-96. [PMID: 18071721 DOI: 10.1007/s00384-007-0395-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 158 |
Cottone M, Orlando A, Mocciaro F. Improving patients' QoL: how the success of treatment can improve workability. Digestive and Liver Disease Supplements 2008;2:17-8. [DOI: 10.1016/s1594-5804(08)60019-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 159 |
Kasparek MS, Glatzle J, Mueller MH, Schneider A, Koenigsrainer A, Kreis ME. Postoperative complications have little influence on long-term quality of life in Crohn's patients. J Gastrointest Surg 2008;12:569-76. [PMID: 18043989 DOI: 10.1007/s11605-007-0412-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 160 |
Perrin JM, Kuhlthau K, Chughtai A, Romm D, Kirschner BS, Ferry GD, Cohen SA, Gold BD, Heyman MB, Baldassano RN, Winter HS. Measuring quality of life in pediatric patients with inflammatory bowel disease: psychometric and clinical characteristics. J Pediatr Gastroenterol Nutr 2008;46:164-71. [PMID: 18223375 DOI: 10.1097/MPG.0b013e31812f7f4e] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 161 |
Kasparek MS, Glatzle J, Temeltcheva T, Mueller MH, Koenigsrainer A, Kreis ME. Long-term quality of life in patients with Crohn's disease and perianal fistulas: influence of fecal diversion. Dis Colon Rectum 2007;50:2067-74. [PMID: 17680311 DOI: 10.1007/s10350-007-9006-5] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 162 |
Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, Finkelstein JA. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007;5:1424-9. [PMID: 17904915 DOI: 10.1016/j.cgh.2007.07.012] [Cited by in Crossref: 683] [Cited by in F6Publishing: 726] [Article Influence: 42.7] [Reference Citation Analysis]
|
| 163 |
Zutshi M, Hull TL, Hammel J. Crohn's disease: a patient's perspective. Int J Colorectal Dis 2007;22:1437-44. [PMID: 17665207 DOI: 10.1007/s00384-007-0332-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 164 |
Saro C, da la Coba C, Casado MA, Morales JM, Otero B. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther 2007;26:1313-23. [PMID: 17850419 DOI: 10.1111/j.1365-2036.2007.03507.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 165 |
Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R. Early versus late surgery for ileo-caecal Crohn's disease. Aliment Pharmacol Ther 2007;26:1303-12. [PMID: 17848181 DOI: 10.1111/j.1365-2036.2007.03515.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 166 |
Moser G. Psychosomatische Aspekte chronisch entzündlicher Darmerkrankungen. Psychosomatik in der Gastroenterologie und Hepatologie. [DOI: 10.1007/978-3-211-69159-5_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 167 |
Casellas F, Rodrigo L, Niño P, Pantiga C, Riestra S, Malagelada JR. Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm Bowel Dis 2007;13:1395-400. [PMID: 17567874 DOI: 10.1002/ibd.20205] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 168 |
Mantzaris GJ, Roussos A, Christidou A, Koilakou S, Kalantzis CN, Petraki K, Sfakianakis M, Karagiannidis A, Polyzou P. The long-term efficacy of azathioprine does not wane after four years of continuous treatment in patients with steroid-dependent luminal Crohn's disease. J Crohns Colitis 2007;1:28-34. [PMID: 21172181 DOI: 10.1016/j.crohns.2007.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 169 |
Zisman TL, Cohen RD. Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. Curr Treat Options Gastro 2007;10:185-94. [DOI: 10.1007/s11938-007-0012-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 170 |
Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46:187-208. [PMID: 17328579 DOI: 10.2165/00003088-200746030-00001] [Cited by in Crossref: 121] [Cited by in F6Publishing: 126] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 171 |
Kunzendorf S, Jantschek G, Straubinger K, Heberlein I, Homann N, Ludwig D, Benninghoven D. The Luebeck interview for psychosocial screening in patients with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:33-41. [PMID: 17206637 DOI: 10.1002/ibd.20050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 172 |
Graff LA, Walker JR, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, Jakul L, McPhail C, Ediger J, Bernstein CN. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 2006;4:1491-501. [PMID: 17162241 DOI: 10.1016/j.cgh.2006.09.027] [Cited by in Crossref: 187] [Cited by in F6Publishing: 205] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 173 |
Leung Y, Geddes M, Storek J, Panaccione R, Beck P. Hematopoietic cell transplantation for Crohn’s disease; is it time? World J Gastroenterol 2006; 12(41): 6665-6673 [PMID: 17075981 DOI: 10.3748/wjg.v12.i41.6665] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 174 |
Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2006;CD004826. [PMID: 17054217 DOI: 10.1002/14651858.cd004826] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 175 |
Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis 2006;12:697-707. [PMID: 16917224 DOI: 10.1097/00054725-200608000-00005] [Cited by in Crossref: 200] [Cited by in F6Publishing: 166] [Article Influence: 11.8] [Reference Citation Analysis]
|
| 176 |
Calvet X, Gallardo O, Coronas R, Casellas F, Montserrat A, Torrejón A, Vergara M, Campo R, Brullet E. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm Bowel Dis 2006;12:692-6. [PMID: 16917223 DOI: 10.1097/00054725-200608000-00004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 177 |
Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell R, Hawkey CJ; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006;55 Suppl 1:i36-58. [PMID: 16481630 DOI: 10.1136/gut.2005.081950c] [Cited by in Crossref: 314] [Cited by in F6Publishing: 328] [Article Influence: 18.5] [Reference Citation Analysis]
|
| 178 |
Casellas F, Vivancos JL, Sampedro M, Malagelada JR. Relevance of the phenotypic characteristics of Crohn's disease in patient perception of health-related quality of life. Am J Gastroenterol 2005;100:2737-42. [PMID: 16393228 DOI: 10.1111/j.1572-0241.2005.00360.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 179 |
Jewell DP, Satsangi J, Lobo A, Probert C, Forbes A, Ghosh S, Shaffer J, Frenz M, Drummond H, Troy G, Turner S, Younge L, Evans L, Moosa M, Rodgers-Gray B, Buchan S. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005;17:1047-52. [PMID: 16148549 DOI: 10.1097/00042737-200510000-00007] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 180 |
Michetti P, Juillerat P, Mottet C, Gonvers JJ, Burnand B, Vader JP, Froehlich F, Felley C. Therapy of mild to moderate luminal Crohn's disease. Digestion 2005;71:13-8. [PMID: 15711043 DOI: 10.1159/000083866] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 181 |
Casellas F, Arenas JI, Baudet JS, Fábregas S, García N, Gelabert J, Medina C, Ochotorena I, Papo M, Rodrigo L, Malagelada JR. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005;11:488-96. [PMID: 15867589 DOI: 10.1097/01.mib.0000159661.55028.56] [Cited by in Crossref: 194] [Cited by in F6Publishing: 158] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 182 |
Fichera A, McCormack R, Rubin MA, Hurst RD, Michelassi F. Long-term outcome of surgically treated Crohn's colitis: a prospective study. Dis Colon Rectum 2005;48:963-9. [PMID: 15785882 DOI: 10.1007/s10350-004-0906-3] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 183 |
Goldfarb NI, Pizzi LT, Fuhr JP, Salvador C, Sikirica V, Kornbluth A, Lewis B. Diagnosing Crohn's disease: an economic analysis comparing wireless capsule endoscopy with traditional diagnostic procedures. Dis Manag. 2004;7:292-304. [PMID: 15671786 DOI: 10.1089/dis.2004.7.292] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 184 |
Janke KH, Klump B, Gregor M, Meisner C, Haeuser W. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:272-86. [PMID: 15735434 DOI: 10.1097/01.mib.0000160809.38611.f7] [Cited by in Crossref: 94] [Cited by in F6Publishing: 79] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 185 |
Sainsbury A, Heatley RV. Review article: psychosocial factors in the quality of life of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005;21:499-508. [PMID: 15740531 DOI: 10.1111/j.1365-2036.2005.02380.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 82] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 186 |
Wiroth JB, Filippi J, Schneider SM, Al-Jaouni R, Horvais N, Gavarry O, Bermon S, Hébuterne X. Muscle performance in patients with Crohn's disease in clinical remission. Inflamm Bowel Dis 2005;11:296-303. [PMID: 15735436 DOI: 10.1097/01.mib.0000160810.76729.9c] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 187 |
Friedman S. General principles of medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:191-208, viii. [PMID: 15177534 DOI: 10.1016/j.gtc.2004.02.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 188 |
Rubin GP, Hungin AP, Chinn DJ, Dwarakanath D. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther 2004;19:529-35. [PMID: 14987321 DOI: 10.1111/j.1365-2036.2004.1873.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 189 |
Langman MJ. The burdens imposed by Crohn's disease: messages for clinicians? Dig Liver Dis 2003;35:849-50. [PMID: 14703878 DOI: 10.1016/j.dld.2003.09.002] [Reference Citation Analysis]
|
| 190 |
Juan J, Estiarte R, Colomé E, Artés M, Jiménez FJ, Alonso J. Burden of illness of Crohn's disease in Spain. Dig Liver Dis 2003;35:853-61. [PMID: 14703880 DOI: 10.1016/j.dld.2003.07.002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 191 |
Cohen RD. IBD: the drugs work...but do the patients? Am J Gastroenterol 2003;98:722-3. [PMID: 12738447 DOI: 10.1111/j.1572-0241.2003.07394.x] [Reference Citation Analysis]
|
